🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "significant breakthrough" in the effort against drug-resistant strains of the infection, according to researchers.

A Worldwide Challenge

Cases of gonorrhoea are increasing globally, with figures suggesting in excess of 82 million new cases each year. Especially elevated rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune advancement in the face of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted therapeutic options presently on offer.”

Medical experts are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has classified it as a "priority pathogen". A tracking program revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Gain Authorization

Zoliflodacin, marketed under the name a brand name, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This STI can lead to significant complications, including infertility. Scientists believe that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the drugmaker GSK, gained clearance in close succession. This treatment, which is also used to treat urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to see it through.

“This approval signifies a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Research Study Data and Global Access

According to results released by a major medical journal, the new drug successfully treated the vast majority of cases of the STI. This puts it on an similar efficacy with the current standard treatment, which uses a dual-drug approach. The study involved hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the authority to register and commercialise the drug in a wide range of developing nations.

Clinicians treating patients have shared optimism. Access to a one-pill regimen such as this is hailed as a "critical tool" for managing the epidemic. This is deemed vital to lessen the impact of the illness for patients and to halt the transmission of untreatable gonorrhoea around the world.